19 February 2025
The Power of Partnership. Switzerland and China set an Example.
In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association...
13 February 2025
Growing Up with HD: Insights & Support Strategies with Siri Hagen Kjølaas
At last year’s EHDN & Enroll-HD Conference in Strasbourg, we had the privilege of interviewing Siri Hagen Kjølaas, Ph.D., to discuss her groundbreaking research...
06 February 2025
SOM Biotech announces Phase 2b study results
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington’s Disease Patients...
30 January 2025
Rare Disease Day 2025 Campaign
The International Huntington Association, in collaboration with the European Huntington Association, is organizing a campaign for Rare Disease Day 2025, on the 28th...
13 January 2025
RDI Launches Youth leadership programme
Rare Diseases International (RDI), announced the launch of the RDI Youth Leadership Programme, an initiative designed to engage and empower young people within the...
16 December 2024
Twelve-year-old publishes children’s book about Huntington's Disease
Toronto student writes book so others will treat her grandpa kindly December 11, 2024 — Toronto, Ontario, Canada Most people have never heard of Huntington’s disease....
11 December 2024
UniQure announces alignment with FDA on key elements of accelerated approval pathway for AMT-130
Yesterday, uniQure issued a press release announcing alignment with the US Food and Drug Administration (FDA) on key elements of an accelerated approval pathway...
09 December 2024
"The Present", documentary featuring Dimitri Poffé, is now available on Youtube
Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South...
09 December 2024
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory...
09 December 2024
Sage Therapeutics ceases development of dalzanemdor in HD
The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data,...